JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266510

Human DR1 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

DR1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 1 and Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

Down regulator of transcription 1 TBP binding, Down-regulator of transcription 1, Dr1 protein, NC 2, NC2-beta, NC2B_HUMAN, Negative co factor 2, Negative cofactor 2-beta, Protein Dr1, TATA box/binding protein associated phosphoprotein DR1, TATA-binding protein-associated phosphoprotein, down-regulator of transcription 1, TBP-binding (negative cofactor 2)

3 Images
Cell Culture - Human DR1 knockout HEK-293T cell line (AB266510)
  • Cell Culture

Unknown

Cell Culture - Human DR1 knockout HEK-293T cell line (AB266510)

Representative images of DR1 knockout HEK293T cells, low and high confluency examples (top left and right respectively) and wild-type HEK293T cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Sanger Sequencing - Human DR1 knockout HEK-293T cell line (AB266510)
  • Sanger seq

Unknown

Sanger Sequencing - Human DR1 knockout HEK-293T cell line (AB266510)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human DR1 knockout HEK-293T cell line (AB266510)
  • Sanger seq

Unknown

Sanger Sequencing - Human DR1 knockout HEK-293T cell line (AB266510)

Allele-1 : 10 bp deletion in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266510-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266510-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266510 Human DR1 knockout HEK-293T cell line", "number":"AB266510-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266510-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266510-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266510 Human DR1 knockout HEK-293T cell line", "number":"AB266510-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266510-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266510 Human DR1 knockout HEK-293T cell line", "number":"AB266510-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266510-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266510 Human DR1 knockout HEK-293T cell line", "number":"AB266510-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
DR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

DR1 also known as negative cofactor 2 (NC2) is an important protein involved in the regulation of gene transcription. It has a molecular weight of approximately 19 kDa and is widely expressed in various tissues. DR1 functions mainly as a transcriptional repressor by interacting with the TATA-binding protein (TBP) therefore inhibiting TBP's ability to initiate the transcription process. By forming a complex with NC2β also known as DRAP1 DR1 can bind to the TATA box during the transcription initiation step regulating the expression of a diverse range of genes.
Biological function summary

DR1 plays a critical role in chromatin remodeling and transcription regulation. It is a part of the DR1/DRAP1 complex which influences the basal transcription machinery. This complex modulates transcription from TATA-containing promoters by altering the TBP-induced DNA bending leading to changes in gene expression patterns that are necessary for cellular homeostasis and development. Its interaction with other transcriptional modifiers helps to finely tune the transcriptional responses of cells.

Pathways

DR1 is integral to the transcriptional regulation pathway specifically affecting the process of transcription initiation. The DR1/DRAP1 complex plays an essential role in maintaining the balance between activators and repressors at the promoter sites. It works closely with proteins like TBP-associated factors (TAFs) which are part of the transcription factor IID (TFIID) complex. This ensures that transcription is controlled precisely allowing cells to respond accurately to various signaling cues.

Dysregulation of DR1 has been linked to cancer and developmental disorders. For instance abnormalities in DR1 expression or function can contribute to the improper regulation of genes that control cell growth potentially leading to tumorigenesis. Additionally mutations or disruptions in DR1-associated pathways might be implicated in developmental disorders where gene transcription processes are adversely affected. Its interaction with other transcription factors involved in these pathways suggests a broader role in disease pathogenesis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com